BONESUPPORT (Q2 Review): Several catalysts before the next report - Redeye

The market focused on the revised 2026 sales growth target rather than another quarter of improving profitability and 40% CER sales growth for US CERAMENT G. While confidence has clearly taken a hit, we argue that the long-term investment case remains intact.

Länk till analysen i sin helhet: https://www.redeye.se/research/1175187/bonesupport-q2-review-several-catalysts-before-the-next-report?utm_source=finwire&utm_medium=RSS